Loss of genetic material, including loss of loci on chromosome arms 6q, 9p, and 10q, occurs frequently in cutaneous melanoma but infrequently in benign melanocytic nevi or other melanocytic lesions, suggesting that these genetic alterations are important in the development and progression of melanoma. To examine whether allelic loss is of prognostic importance in melanoma, disease-free survival was related to loss of heterozygosity on 6q, 9p and 10q in 83 individuals with sporadic primary cutaneous melanoma. Loss of chromosome arms 6q and 10q were each signi®cantly associated with a poorer clinical outcome (P=0.013 and P=0.001 respectively). In a subgroup of 41 subjects whose primary tumours were allelotyped, the fractional allelic loss (FAL) at 39 autosomal arms also signi®cantly correlated with disease-free survival (P=0.013), with an increase in FAL associated with a poorer outcome; this association remained signi®cant when controlled for tumour thickness (P=0.035). In addition, a greater proportion of cells were immunopositive for Ki67 antigen, p53 and p21 WAF1 protein in the primary melanomas than in the benign melanocytic nevi, however, only p53 overexpression was signi®cantly associated with improved survival (P=0.041).
Introduction
At present there are a limited number of therapeutic modalities for metastatic melanoma, and most patients with cutaneous melanoma who develop a recurrence or metastasis eventually die from their disease (Roses et al., 1983; Barth et al., 1995; Lee et al., 1995) . There is an urgent need for predicting those individuals in whom the melanoma will recur following excision of the primary lesion, and who could perhaps bene®t from further treatment at an early stage. Investigations on cutaneous melanoma have demonstrated that multiple genetic abnormalities exist within these tumours (reviewed in Rees and Healy, 1996) . Cytogenetic studies have detected gains and losses of genetic material on multiple chromosomes, and subsequent studies on loss of heterozygosity (LOH) have con®rmed the ®nding of frequent allelic loss (Cowan et al., 1988; Dracopoli et al., 1989; Trent et al., 1990; Millikin et al., 1991; Fountain et al., 1992; Isshiki et al., 1993 Isshiki et al., , 1994 Herbst et al., 1994; Holland et al., 1994; Walker et al., 1994; Healy et al., 1995 Healy et al., , 1996a Thompson et al., 1995) . Recent work has shown that 6q, 9p and 10q are the chromosome arms most frequently lost in this tumour, with evidence that allelic losses on 6q and 10q may be responsible for the malignant phenotype in this neoplasm (Healy et al., 1996a) . Although germline p16
INK4
(and p19 ARF ) mutations are present in some families with hereditary melanoma, p16 INK4 mutations are uncommon in sporadic melanoma, and while this gene may be inactivated via another mechanism (such as methylation or homozygous deletion) there is still some debate as to whether this is the sole target of 9p loss or whether there are additional relevant tumour suppressor genes on 9p (Fountain et al., 1992; Holland et al., 1994; Hussussian et al., 1994; Kamb et al., 1994; Ohta et al., 1994; Gruis et al., 1995a,b; Merlo et al., 1995; Puig et al., 1995; Quelle et al., 1995; Flores et al., 1996; Healy et al., 1996b; Kim et al., 1997; Wiest et al., 1997) . Candidate tumour suppressor genes on 6q and 10q include AIM1 and PTEN/MMAC1 respectively, however, whether these genes are inactivated during primary cutaneous melanoma development and progression is unclear at present (Ray et al., 1997; Li et al., 1997; Steck et al., 1997) .
In other cancer systems genetic alterations, including LOH and the fractional allelic loss (FAL, i.e. the total LOH for all the chromosome arms investigated in a given tumour), have been found to correlate with the tumour grade, lymph node status, and clinical outcome (Jen et al., 1994; Field et al., 1995; Takahashi et al., 1995; Prescher et al., 1996; Gabra et al., 1996) . Investigation for deletion of chromosome arms 6q, 9p and 10q in melanoma could potentially provide important prognostic information in patients with this neoplasm. Some (but not all) studies on DNA ploidy in melanoma have suggested that individuals with tumours exhibiting aneuploidy have a poorer outcome, but there is little information on which chromosomes are responsible for this (Muhonen et al., 1992; Heaton et al., 1993; Scheistroen et al., 1995; Umebayashi and Otsuka, 1995) . Trent et al. (1990) investigated metastatic melanomas for cytogenetic aberrations in relation to clinical outcome, and documented that individuals with structural abnormalities of chromosomes 7 and 11 had signi®cantly shorter survival than patients without these abnormalities. However, metastatic melanoma is a late stage of disease, and nearly all patients with metastases will eventually die from their melanoma (Barth et al., 1995; Lee et al., 1995) . Knowledge of which individuals with primary melanoma will go on to develop metastases is clinically more relevant, and we therefore decided to focus on primary melanomas to determine whether allelic loss provides useful prognostic information.
Increased proliferation and p53 immunopositivity have been shown to correlate with higher recurrence rates and reduced survival in certain cancers, and there is some evidence that these indices are associated with more advanced melanoma, and may help predict the subsequent development of metastases from this tumour (Bouzubar et al., 1989; Stretch et al., 1991; Quinlan et al., 1992; Sun et al., 1992; Allred et al., 1993; Furihata et al., 1993; Ishida et al., 1993; Florenes et al., 1994; Maeda et al., 1994; Ramsay et al., 1995; Boni et al., 1996) . In addition, there is recent con¯icting evidence that altered regulation of p21 WAF1 protein (also known as melanoma dierentiation associated-6 (mda-6)), a downstream eector of p53, occurs in more invasive melanomas (Jiang and Fisher, 1993; Jiang et al., 1995; Vidal et al., 1995; Wang and Becker, 1996) . We have therefore also studied the expression of the Ki67 antigen (a marker of proliferation), p53 and p21 WAF1 protein in patients with primary cutaneous melanoma in relation to the clinical outcome.
Results
LOH of chromosome arms 6q, 9p and 10q and the association of loss of these arms with clinical outcome was investigated in a total of 83 sporadic primary cutaneous melanomas. The depth of invasion (Breslow thickness) of the melanoma varied from 0.4 mm to 16.9 mm (median 3.0 mm). Allelic losses were detected in 14 of 53 informative cases for 6q, 24 of 51 informative cases for 9p, and 17 of 54 informative cases for 10q. In the present study, although loss of 9p and 10q was observed at all depths of invasion of the primary melanoma, LOH of 6q was only identi®ed in melanomas that were deeper than 1.5 mm. LOH at 39 non-acrocentric autosomal arms had been previously investigated in a subgroup of 41 of the 83 melanomas (Healy et al., 1996a) , and the FAL for each melanoma calculated from the number of chromosome arms lost per tumour divided by the total number of chromosome arms heterozygous in the tumour. FAL ranged from 0.000 to 0.548 (median 0.093). Over-expression of the Ki67 antigen, and of the tumour suppressor gene protein products p53 and p21 WAF1 was investigated in 39 of the 41 melanomas that had been allelotyped. The percentage tumour cells positive for Ki67 ranged from 0.0 to 55.3 (median 9.4), and from 0.0 to 92.5 (median 15.0) and 0.0 to 75.0 (median 11.0) for p53 and for p21 WAF1 respectively; by contrast, the percentage nevus cells positive ranged from 0.0 to 0.1 (median 0.01) for Ki67, 0.0 to 10.0 (median 0.0) for p53, and 0.0 to 10.0 (median 0.03) for p21 WAF1 in the 32 benign melanocytic nevi.
In the analysis of the disease-free survival time one individual was omitted because of having a metastasis at initial presentation, thereby reducing the number of informative cases to that outlined in Table 1 . Duration of follow-up after excision of the primary melanoma ranged from 1 month to 14 years 3 months (median 24 months) in the 45 individuals who developed a recurrence/metastasis or died from melanoma, and from 23 months to 15 years 3 months (median 5 years 2 months) in the 37 cases with disease-free survival. There was no evidence that LOH of chromosome arm 9p was related to clinical outcome, however, there was some evidence that patients who had LOH of either 6q or 10q were more likely to have a recurrence of the tumour, develop a metastasis, or die from their melanoma than those who retained these loci (P=0.013 and 0.001 respectively, Figure 1 and Table  1 (section A)). Disease-free survival was also reduced in patients with melanomas demonstrating a higher FAL score (P=0.013), Figure 1 and Table 1 ). Disease-free survival was not associated with immunopositivity for Ki67 or p21 WAF1 , but was prolonged in patients with a greater percentage of p53 over-expression in the primary melanoma (P=0.041, Table 1 ).
Because the depth of invasion of the primary melanoma is the best prognostic factor at the present Hazard ratios, 95% con®dence intervals (95% CI), and P-values are given in part A, and the corresponding quantities, after adjustment for depth of invasion, are given in part B.
a Number of events signi®es number of individuals with recurrence, metastasis or death from melanoma. b Note that the hazard ratio listed is for every 0.01 unit increase in the FAL, therefore the hazard ratio for a melanoma with a FAL score of 0.25 relative to a melanoma whose FAL score is 0.0 is 2.54 (1.31 ± 4.72), and similarly 2.25 (1.16 ± 4.39) when adjusted for depth of invasion. The hazard ratios for Ki67, p53 and p21
WAF1 are for a change of one percentage point in each variable time (Breslow, 1970; Morton et al., 1993) , and because this variable is currently used clinically for predicting outcome, we also analysed survival in relation to the above genetic alterations with the analyses adjusted for the depth of invasion (Table 1 , (section B)). The relationship between LOH of 6q or 10q and the clinical outcome, when adjusted for invasion, was reduced but was not formally signi®cant on statistical testing (P=0.23, and P=0.054 respectively). However, the FAL was signi®cantly associated with survival independent of tumour thickness, with a reduced survival in patients whose primary melanomas had a higher FAL score (P=0.035, ) and vice versa. Neither was a relation detected between Ki67 antigen expression and p53 or p21 WAF1 immunopositivity, the FAL per tumour or loss on individual chromosome arms 6q, 9p or 10q, and between p53 or p21 WAF1 protein expression and LOH of 6q, 9p and 10q (or 6p and 17p, which were detected in only a small number of cases) or FAL.
Discussion
One aim of understanding the genetics of cutaneous melanoma is to identify individuals susceptible for this neoplasm at an early stage (prior to the development of a melanoma) so that appropriate preventative strategies could then be targeted to these individuals. Although recent progress has been made into the genetics of melanoma susceptibility, for example germline p16
INK4 mutations in families with hereditary melanoma and melanocortin 1 receptor variants in sporadic melanoma cases, it is likely that large numbers of individuals will continue to develop cutaneous melanoma, (even if, as a result of screening for melanoma, the lesions are detected at an earlier stage of invasion) (Hussussian et al., 1994; Kamb et al., 1994; Gruis et al., 1995a; Quelle et al., 1995; Valverde et al., 1996) . At present the best prognostic information can be obtained from histological measurement of the depth of invasion of the primary melanoma, yet a signi®cant number of subjects with thin melanomas eventually die from their disease (Breslow, 1970; Morton et al., 1993) . Because the clinical behaviour of the melanoma is most likely to result from the genetic alterations that have occurred within the tumour, genetic changes within the lesion could potentially provide more information on prognosis than the depth of invasion alone.
In the present study allelic losses of loci on 6q and 10q were associated with a poorer clinical outcome, lending further support that genes on these chromosome arms are important in the neoplastic behaviour of the melanoma. Although the P values for these losses did not achieve signi®cance when controlled for the tumour thickness, it is biologically plausible that LOH of these two arms underlies (at least partly) the prognostic information aorded by the Breslow thickness. The results of LOH of 6q, 9p, and 10q in the 83 melanomas in this study con®rms that these three chromosome arms are frequently deleted in primary melanomas and further suggests that loss of 6q occurs at a later stage in melanoma progression than loss of 9p and 10q (Healy et al., 1996a) . However, based on the FAL scores, the results suggest that the overall level of genomic instability (as well as losses of 6q and 10q) may determine the clinical behaviour of the melanoma and the ultimate clinical survival. This association of higher FAL scores with a poorer clinical Allelic loss and survival in melanoma E Healy et al outcome, independent of the depth of invasion, suggests that this variable might allow the identification both of individuals with thin melanomas who will eventually die from their tumour and of subjects with paradoxically thick melanomas in whom the melanoma will not metastasize.
Although we found associations between loss of certain individual chromosome arms and a poorer clinical outcome in individuals with cutaneous melanoma, our results are potentially an underestimate regarding the eects on prognosis by the relevant genes on these chromosome arms. It is likely that other mechanisms of inactivating tumour suppressor genes are involved in this neoplasm (for example mutation, methylation, and homozygous deletion) such that LOH only detects a proportion of cases where genes on 6q and 10q are inactivated. In addition, the size of the deleted area might be important; in support of this Puig et al. (1995) recently reported on a higher proportion of melanomas with large deletions on 9p developing metastases by comparison with melanomas with smaller or no deletions of this chromosome arm.
The results in the present study also suggest that allelic losses of 6q and 10q, and FAL are more informative than proliferation markers, such as Ki67 antigen expression, in predicting outcome from melanoma. This may be because tumourigenesis involves more than enhanced proliferation alone; neoplastic cells also need to be able to invade, avoid the host's immune defences, undergo alterations in cellcell interactions, and metastasize, and thus would require alterations in genes involved in these processes as well as in genes responsible for controls on proliferation (Weinberg, 1995) . In addition, although p53 immunopositivity was associated with disease-free survival, the fact that p21 WAF1 expression exhibited no relationship to survival (and to p53 immunostaining) suggests that p53's`protective' eects may not be mediated via the p21 WAF1 pathway which is involved in the regulation of proliferation (El-Deiry et al., 1993; Harper et al., 1993) . These results further indicate that p21 WAF1 upregulation in cutaneous melanoma is likely to be predominantly via p53 independent pathways. However, some melanomas which were immunopositive for p21 WAF1 contained foci within the tumour which were strongly immunopositive for p53 but which were p21 WAF1 negative. Because p21 WAF1 is mutated infrequently in melanoma (Vidal et al., 1995) , it is likely that p53 was mutated in these clones, and suggests that when the TP53 gene becomes mutated (albeit at a low frequency) in cutaneous melanoma it occurs as a late event during melanoma progression (Castresana et al., 1993; Albino et al., 1994; Florenes et al., 1994; Lubbe et al., 1994; Montano et al., 1994) .
Materials and methods

LOH analysis
Following microdissection to reduce contamination with normal tissue, and sodium dodecyl sulphate/proteinase K digestion for 5 days at 378C, genomic DNA was extracted by the phenol chloroform/ethanol precipitation method (Jackson et al., 1992) from paran-embedded primary cutaneous melanomas of 83 patients. DNA from normal skin or peripheral blood was used as control in each case. In order to avoid co-extracted melanin inhibiting the PCR, deeply pigmented tumours were also subjected to elutip-d chromatography. For LOH analysis melanoma and normal DNA was ampli®ed in a 10 ml PCR containing 1 pmol of microsatellite primers (obtained from Research Genetics, Huntsville, AL) with one primer end-labelled with g 32 P-ATP, 100 ng of genomic DNA, 200 mM deoxynucleotide triphosphates, and 1 unit of Taq polymerase. PCR consisted of 30 cycles of 1 min at 948C, 1 min at 558C, and 1 min at 728C, with an extension time of 10 min at 728C during the ®nal cycle. The products were electrophoresed through 6% denaturing polyacrilamide gels, which were subsequently dried and exposed to Fuji XR ®lm for 1 ± 48 h. Allelic loss was scored in informative cases which exhibited a signi®cant reduction of one allele in the tumour DNA as compared with the control DNA. LOH of chromosome arms 6q, 9p, and 10q was investigated in all 83 cases, whereas the FAL at 39 autosomal arms had been previously investigated in 41 tumours (Healy et al., 1996a) . The microsatellite markers used in this study have been documented previously (Healy et al., 1996a) .
Immunohistochemistry
Expression of the Ki67 antigen, p53, and p21 WAF1 proteins were studied by immunohistochemistry in 39 cases (in whom LOH had been investigated) using the monoclonal antibodies MIB1 (Immunotech, France), DO7 (Novocastra, Newcastle, UK), and EA10 (El-Deiry et al., 1995; kind gift from Dr Bert Vogelstein, Johns Hopkins Oncology Center) respectively. Antigen retrieval on the paranembedded melanomas was carried out by microwaving 4 mm sections for 10 min in sodium citrate buer (pH 6.0) in a 600 watt microwave oven. The sections were then incubated at room temperature with normal rabbit serum (1 : 10 dilution) for 10 min, followed by the addition of primary antibody (1 : 500 dilution for MIB1 and EA10, 1 : 50 dilution for DO7,) for 30 min. A biotinylated secondary rabbit anti-mouse antibody (1 : 500 dilution) was applied for 30 min, followed by a streptavidin-biotinperoxidase detection system (Dako) using diaminobenzidine as the substrate, and ®nally the sections were counterstained with haematoxylin. The percentage tumour cells stained positively with primary antibody was calculated by two independent observers. For Ki67 over 1000 cells per tumour were counted and the number of these cells with positive nuclei then expressed as a percentage of the total. For p53 and p21 WAF1 , because there was a greater range in the number of tumour cells positive for these proteins, the percentage positive melanoma cells was estimated from low and high power ®elds rather than counting individual nuclei. Immunostaining for Ki67, p53 and p21 WAF1 was similarly carried out on 32 benign melanocytic naevi for comparison.
Clinical outcome
All reading of results of LOH and immunostaining was carried out prior to obtaining (and therefore blinded to) the information on patient outcome. Details of patient survival, recurrence and/or metastasis of the neoplasm were obtained from the medical records, by interview, or from the death certi®cate. Statistical analysis was carried out using STATA (STATA Corporation, 1997). Survival time was assumed to follow a Weibull distribution and a proportional hazards model was ®tted (Collett, 1994 ). This assumption was tested using quantile plots and found to be satisfactory. The statistical analyses are con®ned to the cases where informative covariate values were obtained and it is assumed that there is no systematic dierence between these and the uninformative cases.
